Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial-Reference-Cited by-同舟云学术

Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial

Published:2021-07-22 Issue:8 Volume:41 Page:685-699
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Li Xiao^ORCID,Bilcke Joke^ORCID,van der Velden Alike W.^ORCID,Bongard Emily^ORCID,Bruyndonckx Robin^ORCID,Sundvall Pär-Daniel^ORCID,Harbin Nicolay J.^ORCID,Coenen Samuel^ORCID,Francis Nick^ORCID,Bruno Pascale,Garcia-Sangenis Ana^ORCID,Glinz Dominik^ORCID,Kosiek Katarzyna,Mikó-Pauer Réka,Radzeviciene Jurgute Ruta,Seifert Bohumil^ORCID,Tsakountakis Nikolaos,Aabenhus Rune^ORCID,Butler Christopher C.,Beutels Philippe^ORCID

Funder

European Commission’s Seventh Framework Programme: Platform for European Preparedness Against (Re-)emerging Epidemics

Research Foundation - Flanders

Methusalem

The Healthcare Committee, Region Västra Götaland, Sweden

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01057-y.pdf

Reference24 articles.

1. Collaborators GBDI. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69–89.

2. WHO surveillance case definitions for ILI and SARI. https://www.who.int/influenza/surveillance_monitoring/ili_sari_surveillance_case_definition/en/.

3. Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health. 2012;12:968.

4. Federici C, Cavazza M, Costa F, Jommi C. Health care costs of influenza-related episodes in high income countries: a systematic review. PLoS ONE. 2018;13(9):e0202787.

5. National Institute for Health and Care Excellence: amantadine, oseltamivir and zanamivir for the treatment of influenza. 25/02/2009 edn; 2009. https://www.nice.org.uk/guidance/ta168.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the Clinical Courses of Children With Human Rhinovirus/Enterovirus to Children With Other Respiratory Viruses in the Outpatient Setting;Pediatric Infectious Disease Journal;2023-09-07

2. Cost-Effectiveness of Vaccination of Older Adults with an MF59®-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden;Vaccines;2023-03-29

3. Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review;PharmacoEconomics;2022-12-14

4. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries;The European Journal of Health Economics;2022-09-22

5. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults;The Journal of Infectious Diseases;2022-03-31